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   Abstract.      In May 2005, visceral leishmaniasis (VL) was recognized for the first time in Libo Kemken, Ethiopia, 
a highland region where only few cases had been reported before. We analyzed records of VL patients treated from May 
25, 2005 to December 13, 2007 by the only VL treatment center in the area, maintained by Médecins Sans Frontières-
Ethiopia  ,   Operational Center Barcelona-Athens. The median age was 18 years; 77.6% were male. The overall case fatality 
rate was 4%, but adults 45 years or older were five times as likely to die as 5–29 year olds. Other factors associated with 
increased mortality included HIV infection, edema, severe malnutrition, pneumonia, tuberculosis, and vomiting. The VL 
epidemic expanded rapidly over a several-year period, culminating in an epidemic peak in the last third of 2005, spread 
over two districts, and transformed into a sustained endemic situation by 2007.     
    INTRODUCTION 
  In 2005, a new epidemic of visceral leishmaniasis (VL) 
was reported in the district of Libo Kemkem in northwest-
ern Ethiopia.  1   The outbreak occurred in a highland region, 
where few cases of the disease had ever been reported before. 
The initiating event was hypothesized to have been the intro-
duction of the parasite, probably on multiple occasions, by 
migrant agricultural laborers returning to their villages from 
seasonal work on the border with Sudan.  1–4   Health practitio-
ners in the district had no previous experience with VL, and 
early cases were attributed to drug-resistant malaria, leading 
to a delay in recognition and high mortality early in the epi-
demic.  1   By the time the etiology was confirmed, available data 
suggested that some cases had symptom onset at least 2 years 
earlier, and the outbreak had already spread beyond the vil-
lages that were first affected. More than one species and sev-
eral genotypes of   Leishmania   were identified in human and 
canine specimens, supporting the hypothesis that multiple 
introductions had occurred.  1   The Addis Zemen Health Center 
(AZHC), maintained by Médecins sans Frontières-Ethiopia, 
Operational Center Barcelona-Athens, was the only facility 
in the area with VL diagnostic capability and anti-  leishmanial 
drugs, and their personnel identified the cause of the epide-
mic and treated almost all of the VL patients. Their records 
therefore provide a fairly complete picture of the course of the 
outbreak from the time it was first recognized. Community-
based data collected in October 2005 suggested that a large 
proportion of patients who became ill in 2003 and 2004 may 
have died before their disease was recognized; however, once 
AZHC began offering treatment of VL, the mean duration 
of illness before diagnosis fell quickly, and ascertainment in 
villages near Addis Zemen was likely to be high.  1   Using data 
from AZHC, we therefore performed a series of analyses to 
describe the patient population and characterize the course of 
the epidemic from 2004 to 2007. 
   MATERIALS AND  METHODS 
  Addis Zemen is the capital of Libo Kemkem wereda (dis-
trict), in the Amhara Region of northwestern Ethiopia (aver-
age altitude 2,000 m above sea level). The town is located 
between Bahir Dar and Gondar on the major road connect-
ing Addis Ababa to the Red Sea through Port Sudan. Most 
patients treated at AZHC lived in Libo and Fogera districts 
(estimated populations 198,374 and 226,595, respectively), 
located across from each other on the north and south banks 
of the Rib River. 
  The data in this analysis included all primary VL cases diag-
nosed and treated at AZHC between May 25, 2005 (when 
the etiology of the outbreak was first recognized as VL) and 
December 13, 2007. The WHO operational case definition for 
VL was used: a person showing clinical signs (prolonged irregu-
lar fever for > 2 weeks, splenomegaly, and/or weight loss) with 
serologic and/or parasitologic confirmation (when feasible).  5  
Malaria was ruled out based on negative blood smears. Most 
patients had their diagnosis confirmed by the direct aggluti-
nation test (DAT). The DAT was performed using standard 
methods and antigen from ITG-Belgium; titers ≥ 1:3,200 were 
considered positive.  6   If the diagnosis could not be confirmed by 
the results of DAT on two separate occasions (because of discor-
dant results or repeatedly borderline titers of 1:800 or 1:1,600), 
splenic aspirate was used to confirm the diagnosis. A small num-
ber of patients had their diagnosis confirmed using the InBios 
Kala-azar Detect rK39 rapid   test (InBios International, Seattle, 
WA), which was not yet registered in the country at the time. 
These patients were diagnosed during and just after an earlier 
study that used these rapid tests; the study investigators pro-
vided the remainder to AZHC after the field work ended.  1   
  We calculated dates of symptom onset retrospectively, based 
on dates of diagnosis and the duration of illness reported in the 
clinical record. Spleen size below the costal margin was mea-
sured in centimeters and categorized based on the distribution 
by age group; quartiles were defined for children < 2, 2.1–5, 374 HERRERO AND OTHERS
5.1–14, and 15 years of age or older. The top two quartiles were 
compared with the bottom two quartiles of spleen size as the 
referent. Hemoglobin testing was conducted for a proportion 
of patients. Until January 2007, a manual hemoglobinometer 
(Hemocue Hb 201  +, HemoCue AB, Angelholm, Sweden) was 
used. Later in the course of the epidemic, the facility obtained 
a SYSMEX (KX-21 Automated Hematology Analyzer, Sysmex 
Corporation, Kobe, Japan  ) instrument that produced complete 
blood counts for the most severe patients. Adults were offered 
systematic HIV screening through a voluntary counseling and 
testing program beginning in December 2006. Parallel test-
ing was performed using the Determine Rapid HIV1/2 Test 
(Inverness Medical, Waltham, MA) and Capillus HIV1/HIV2 
Rapid Test (Trinity Biotech, Wicklow, Ireland). For specimens 
with discordant results, the Uni-gold Recombigen HIV (Trinity 
Biotech) was used as the third test. Written parental consent was 
obtained before testing children for suspected HIV infection. 
  Body mass index (BMI) was calculated (weight in kilograms 
divided by the square of the height in meters) for adults and 
children older than 5 years. Weight-for-height Z scores were 
calculated for children using software available on the World 
Health Organization website ( http://www.who.int/childgrowth/
software/en/index.html  ). This software uses newly released 
data from an international reference population.  7–9   Severe 
malnutrition was defined by the presence of bilateral lower 
extremity edema or the appropriate anthropometric criteria 
depending on age: weight-for-height Z scores < −3 for partici-
pants ≤ 5 years; BMI-for-age Z score < −3 for those between 
5 and 19 years; and BMI < 16.0 kg/m  2   for those older than 19 
years. Severe anemia was defined as hemoglobin < 7.0 g/dL. 
  Statistical analyses were performed in SAS 9.0. We modeled 
predictors of death first through univariate logistic regression 
analyses, followed by a backwards stepwise elimination pro-
cedure beginning with variables significant at 0.10. Collinear 
variables, such as edema and severe malnutrition, were not 
included in the same model. Cumulative annual incidence 
data were mapped at the kebele (subdistrict) level within Libo 
and Fogera, the two most affected districts. 
   RESULTS 
  A total of 2,543 leishmaniasis patients were treated at 
AZHC between May 25, 2005 and December 13, 2007. Of 
these, 2,364 (92%) were diagnosed with primary VL; 31 
(1.2%) patients were recorded as having a relapse of previ-
ously treated VL, 39 (1.5%) as post–kala-azar dermal leish-
maniasis, 106 (4.2%) as cutaneous leishmaniasis, and 3 (0.1%) 
as mucocutaneous leishmaniasis. The remainder of the analy-
sis focused on the 2,364 patients with primary VL. A total of 
2,174 patients were diagnosed by DAT, whereas 86 had the 
diagnosis confirmed by splenic aspirate and 104 by rK39 rapid 
test. The median age of VL patients was 18 years (range, 0.8–
80 years); 1,834 (77.6%) were male. Female patients were sig-
nificantly younger than male patients (median age, 11 versus 
20 years;   P   < 0.0001). Of 578 patients younger than 10 years 
old, 235 (40.7%) were girls, compared with 21.0% (136/647) of 
patients 10–19 years old and 13.7% (156/1136) of patients 30 
years or older (χ  2   for linear trend, 151.0;   P   < 0.0001). Of 2,306 
patients with data regarding spleen size on admission, 2,168 
(94%) had palpable splenomegaly; the median spleen size was 
8.5 cm (range, 1–28 cm). Admission measurements of weight 
and height were available for 2,261 patients. A large propor-
tion of patients showed signs of severe malnutrition: 39% of 
children < 5 years had weight-for-height and 41% of children 
5–19 years old had BMI-for-age below −3 Z scores, whereas 
26% of adults had a BMI < 16 kg/m  2  . Of 1,860 patients with 
data available, 365 (20%) had bilateral lower extremity edema 
on physical examination. The median hemoglobin on admis-
sion was 8.1 g/dL. 
  Ninety-seven percent (2,296/2,364) of VL patients were 
treated with sodium stibogluconate. In 2007, a limited supply 
of liposomal amphotericin was available but was used only for 
the most gravely ill patients; a total of 48 (2%) patients were 
treated with liposomal amphotericin, and 20 (0.8%) received a 
combination of sodium stibogluconate and liposomal ampho-
tericin. Of 2,177 VL patients with outcome data, 87 (4%) 
were known to have died. Outcome data were missing for 187 
patients, including 38 patients who defaulted and 13 who were 
transferred. The case-fatality rate showed a J-shaped curve: 
mortality was lowest in patients 5–29 years old, whereas adults 
45 years or older were five times as likely to die as patients in 
the 5- to 29-year age group (  Figure 1    ). In addition to age, other 
factors associated with increased risk of death included HIV 
infection, the presence of edema, severe malnutrition, pneu-
monia,  tuberculosis,  and  vomiting  ( Table  1              ).  Vomiting  was 
more common in the small group of patients treated with lipo-
somal amphotericin (23/48 [47.9%] compared with 74/2,295 
[3.2%] patients treated with sodium stibogluconate;   P   < 0.0001 
by two-tailed Fisher exact test). The severity of illness in this 
patient group lends support to the hypothesis that vomiting 
was a marker for more severe VL and not an outcome of anti-
monial therapy. Before December 2006, only 2% of patients 
had HIV testing compared with 82% of patients admitted in 
or after December 2006. Data were not systematically col-
lected regarding jaundice or bleeding. In a multivariable logis-
tic regression model, age group, edema, severe anemia, HIV 
status, and tuberculosis were identified as independent predic-
tors  of  death  ( Table  2           ). 
  The duration of symptoms was recorded for 1,909 (80%) 
of 2,364 patients, allowing us to calculate the month of illness 
onset. Cases missing duration data did not differ from those 
with known duration in terms of age or sex distribution but 
were more likely to have been treated in 2005 than in 2006 
or 2007 (  P   < 0.001 for 2005 compared with 2006–2007). The 
  Figure   1.        Case-fatality rate by age group among 2,177 primary 
VL patients treated from May 2005 to December 2007 at the Addis 
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AZHC treated a total of seven VL cases with calculated onset 
dates between March 2003 and June 2004. From June 2004 
onward, VL incidence rose sharply, peaking in the latter half 
of 2005 and falling in 2006 (  Figure 2    ). Beginning in mid-2006, 
a higher proportion of patients also came from more distant 
districts. These patients were older, more likely to be male, and 
had been ill longer at the time of admission compared with 
patients who came from Libo and Fogera, the two districts 
closest to AZHC (  P   <  0.001  for  each  comparison;   Table  3              ). 
As noted in earlier analyses, the mean illness duration in 
patients from Libo and Fogera fell from 5.8 months in May to 
August 2005 to 3.0 months thereafter. 
  Within Libo and Fogera districts, VL cases became more 
geographically dispersed from 2004 to 2006 (  Figure 3A    –C). 
Sixty-seven percent of cases with onset in 2004 came from Bura 
kebele, where the epidemic began (  Figure 3A  ). However, only 
15.7% of 2005 cases and 3.9% of 2006 cases came from Bura 
kebele. In the latter 2 years of the outbreak, more patients 
came from other kebeles of Libo (43.1% of 2005 and 31.7% 
of 2006 cases) and from Fogera district (30.6% of 2005 and 
39.3% of 2006 cases) than from Bura kebele. By 2006, the 
cumulative annual incidence had diminished throughout the 
districts (  Figures 2   and   3C  ). 
   DISCUSSION 
  Data from VL cases treated at AZHC tell the story of an 
epidemic that expanded rapidly over a several-year period, 
culminating in an epidemic peak in the last third of 2005, 
spread over two districts, and transformed into a low inci-
dence endemic situation by 2007. During the first 3 months 
after recognition of the epidemic, the mean duration of ill-
ness fell sharply, reflecting the identification and treatment of 
patients whose diagnosis had been delayed during the period 
that the etiology was unknown. The response to the epidemic 
by AZHC staff was instrumental in maintaining the case fatal-
ity at or near 4%, a low rate under field conditions. A substan-
tial proportion of patients undoubtedly died at home before 
recognition of the epidemic,  1   and some deaths that occurred 
after discharge likely went unrecorded. Case follow-up in this 
area is limited by distance, poverty, lack of public transport, 
and resulting constraints on the ability to travel to facilities. 
The fact that VL patients from more distant districts were sig-
nificantly older and more likely to be male compared with 
those from Libo and Fogera suggests that patients who are 
younger and/or female may be less likely to be able to travel to 
AZHC, reflecting more marked barriers to health care access 
for these groups. Deaths from untreated VL may be occurring 
  Table 1   
  Univariate analyses of factors associated with death among 2,177 pri-
mary VL patients* treated from May 2005 to December 2007 at the 
Addis Zemen Health Center, Libo District, Ethiopia 




(95% CI)   P 
Age group (years)
< 5 239 5.4 2.2 (1.2–4.2) 0.02
5–14 655 2.4 Referent
15–29 850 2.6
30–44 327 7.0 2.9 (1.7–5.0) < 0.0001
45–80 106 12.3 5.4 (2.8–10.5) < 0.0001
Sex
Male 1,689 3.9 Referent
Female 487 4.3 1.1 (0.7–1.8) 0.69
Spleen size
Below median for age 988 3.5 Referent
50th to 75th percentile 531 4.0 1.0 (0.6–1.7) 0.94
Above 75th percentile 538 4.3 1.1 (0.7–1.9) 0.70
HIV status
Positive 50 10.0 5.4 (1.5–19.4) < 0.0001
Negative 248 2.0 Referent
Unknown 1,879 4.1 2.1 (0.8–5.2) 0.12
Severe anemia
Hemoglobin < 7.0 159 8.8 4.7 (1.86–11.9) 0.0011
Hemoglobin ≥ 7.0 348 2.0 Referent
Unknown 1,670 4.0 2.0 (0.91–4.4) 0.084
Edema
Yes 365 10.7 5.3 (3.3–8.6) < 0.0001
No 1,495 2.2 Referent
Severe malnutrition†
Yes 922 6.1 2.6 (1.6–4.0) < 0.0001
No 1,255 2.5 Referent
Pneumonia
Yes 230 7.0 2.1 (1.2–3.6) 0.02
No 1,937 3.5 Referent
Diagnosis of TB
Yes 22 16.7 5.7 (1.9–17.3) 0.002
No 2,145 3.9 Referent
Vomiting
Yes 95 9.5 2.8 (1.3–5.7) 0.0056
No 2,071 3.6
    *      These analyses exclude 187 VL patients whose outcome data were missing or ambiguous.   
    †      Severe malnutrition defined by presence of edema or weight-for-length/height Z scores 
< −3 for participants ≤ 5 years; body mass index (BMI) Z score < −3 for those between 5 and 
19 years; BMI < 16.0 kg/m  2   for those older than 19 years.   
  Table 2   
  Multivariable model of risk factors associated with death among 2,177 
VL patients treated from May 2005 to December 2007 at the Addis 
Zemen Health Center, Libo District, Ethiopia 
Risk factor Odds ratio (95% CI)   P 
Age (years)
< 5 1.66 (0.74–3.75) 0.2226
5–29 1.0 —
30–44 3.32 (1.76–6.27) 0.0002
≥ 45 6.61 (3.15–13.9) < 0.0001
Edema 4.93 (2.93–8.29) < 0.0001
Hemoglobin < 7.0 4.43 (1.53–12.8) 0.006
HIV status
Positive 5.96 (1.23–24.0) 0.027
Negative 1.0 —
Unknown 5.82 (1.73–19.6) 0.0044
Tuberculosis 5.18 (1.29–20.8) 0.0205
  Figure   2.        Epidemiologic curve showing cases by month of illness 
onset and location of residence, among 1902 primary VL patients with 
onset between June 2004 and December 2007.       376 HERRERO AND OTHERS
in these districts without being recognized. Low awareness of 
the disease both by health practitioners and local population 
may also decrease recognition of relapses, especially among 
HIV-VL co-infected patients who often have atypical presen-
tations. Because of these factors, the measured case-fatality 
rates are likely to be underestimates. 
  In common with data reviews from other VL treatment 
facilities in the Horn of Africa, we found that young children 
and older patients were much more likely to die than older 
children or young adults.  10   Other predictors of mortality, such 
as severe anemia, severe malnutrition, edema, HIV status, and 
the presence of pneumonia or tuberculosis, were not unex-
pected.  10–12   Severe malnutrition, anemia, and immunosuppres-
sion from HIV all intensify VL morbidity. Bacterial pneumonia 
and tuberculosis are typical secondary infections during VL 
and are often the immediate cause of death. Jaundice has also 
been recognized as an indicator of poor prognosis.  12  We  lacked 
systematic data on jaundice, but vomiting may have been asso-
ciated with hepatic dysfunction. Edema also may have been a 
composite measure, reflecting both severe malnutrition and, in 
some cases, hepatic dysfunction. These data support the con-
tinued use of a severity score to triage patients in need of more 
intensive therapy.  10  
  Although the large number of patients included in this anal-
ysis lends robustness to our findings, the inevitable limitations 
of clinical data constrained our ability to precisely define risk 
factors and their impact. One major limitation is the fact that 
data on HIV status were only available starting in December 
2006; the impact of this factor is almost certainly underesti-
mated in our analysis. Furthermore, we cannot evaluate the 
previously documented association between treatment with 
antimonials and higher mortality in HIV co-infected patients,  13  
  Table 3   
  Characteristics of 2,364 primary VL patients treated from May 2005 to December 2007 at Addis Zemen Health Center, Libo District, Ethiopia, by 
district of residence 
Libo Fogera Other districts All patients
Sex
Male 933 (73.9%) 536 (75.5%) 365 (94.1%)* 1834 (77.7%)
Female 330 (26.1%) 174 (24.5%) 23 (5.9%) 527 (22.3%)
Age (years)
< 5 173 (13.7%) 74 (10.4%) 6 (1.6%) 253 (10.7%)
5–14 431 (34.1%) 226 (31.8%) 33 (8.5%) 690 (29.2%)
15–29 411 (32.5%) 264 (37.2%) 251 (64.7%) 926 (39.2%)
30–44 183 (14.5%) 107 (15.1%) 82 (21.1%) 372 (15.7%)
45–80 67 (5.3%) 39 (5.5%) 16 (4.1%) 122 (5.2%)
Mean age (years) 18.1 19.5   24.7*     19.6
Months of illness before treatment 3.35 3.12     4.27*      3.44
    *      Distribution by sex, age, and duration of illness differs significantly for patients from other districts compared with patients from Libo and Fogera;   P   < 0.001 for each comparison.   
  Figure   3.        Cumulative annual incidence of VL by   kebele   (subdistrict) in Libo and Fogera districts in (  A  ) 2004, (  B  ) 2005, and (  C )  2006.    377 VISCERAL LEISHMANIASIS OUTBREAK IN ETHIOPIA
because our HIV data are incomplete and sodium stiboglu-
conate was the only anti-leishmanial drug available for most 
of the study period. Because of the extremely limited supply, 
liposomal amphotericin was reserved for the most gravely ill 
patients. Other risk factors, such as hemoglobin level, were 
more likely to be measured in the patients with more severe 
illness; nevertheless, the comparison within the subgroup with 
measured hemoglobin supports the view that severe anemia is 
associated with increased mortality risk. 
  Most importantly, these data offer the unique opportunity 
to document the early stages of an epidemic followed by the 
transformation into a situation of sustained endemic transmis-
sion. We know that local VL transmission occurred in this high-
land region in the 1970s, when two apparently autochthonous 
VL cases were described in the neighboring district of Belessa.  2  
More than 25 VL cases were treated at Gondar Hospital in the 
1970s, all in migrant workers returning from the Sudan bor-
der areas.  3   The authors estimated in 1978 that 50,000–100,000 
highland men spent an agricultural season in the Sudan bor-
der area each year  3  ; the current number of seasonal migrants 
is likely to be even higher.   Phlebotomus orientalis  , the known 
lowland vector, was trapped in Belessa in 1972 and in Libo in 
2006.  2,14   Although none of the trapped sand flies were shown to 
be infected with   Leishmania  , the highland vector is assumed to 
be capable of sustaining leishmanial transmission.  2,14   
  Between the 1970s and 2003,   Leishmania   introductions 
must have occurred, but in 2004, a threshold seems to have 
been passed, leading to a period of intense transmission in 
Bura kebele. In the second half of 2004 and in 2005, the inci-
dence of VL in Bura was > 2% per year. In the 2005 survey of 
the most affected village in Bura, 14% of the population was 
reported to have had VL since 2004, and 50% of those tested 
were leishmanin skin test positive.  1   In 2005, during the peak of 
the epidemic, kebeles adjacent to Bura showed equally high 
incidence. However, by 2006, the incidence of new cases of VL 
had fallen sharply in Bura and its neighbors; like the high posi-
tive skin test prevalence, the decline probably reflected satu-
ration of the susceptible population. Nevertheless, low-level 
transmission has continued into 2007 and shows no signs of 
disappearing. This region must now be added to the list of sus-
tained endemic foci of visceral leishmaniasis in Ethiopia. 
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